Physician guidance on topical frequency and coverage area is important because excessive copper delivery to large skin surface areas carries a theoretical accumulation risk
Nausea ranks as the most frequent initial symptom, often described as mild queasiness rather than severe vomiting
Sometimes, after several months on a GLP-1, the weight loss slows down
In the SURMOUT-1 trial 2,539 patients underwent randomization to tirzepatide or placebo and were followed for 72 weeks demonstrating up to 20.9% weight reduction with maintenance dosing versus 3.1% in the placebo group for a net 17.8% weight reduction [35]
Besides, AOD9604 doesnt affect IGF-1 and insulin levels, thus ensuring minimal risk of developing glucose intolerance and diabetes mellitus
C-peptide, which is co-secreted with insulin and serves as a marker of endogenous insulin production, follows a similar pattern